The Daily Brief Indian pharma wants to conquer cancer
17 snips
Sep 29, 2025 Indian pharma is ramping up efforts to tackle cancer, focusing on the shift from generics to biosimilars that show promise for making treatments more affordable. The podcast discusses the complexities involved in biologics, including the manufacturing and testing hurdles they face. Highlighted are companies like Glenmark and Biocon, which are betting big on oncology. Additionally, the RBI's regulatory action against Simple reveals insights into fintech dynamics in India and the emphasis on compliance in the financial sector.
AI Snips
Chapters
Books
Transcript
Episode notes
Biologics Shift Cancer Treatment Focus
- Biologics let medicine target cancer far more precisely than chemotherapy does.
- They modulate immune responses or bind specific cancer markers, reducing collateral damage to healthy tissue.
Three Pillars Of Cancer Biologics
- There are three main classes of cancer biologics: monoclonal antibodies, immune checkpoint inhibitors, and antibody drug conjugates.
- Each class works differently, from targeting markers to unblocking immune attacks or delivering chemo precisely to cancer cells.
Biologics Are Manufacturing-Intensive
- Biologics are extremely hard and expensive to manufacture because they are produced in living cells under precise conditions.
- Minor variations can ruin batches and regulatory trials form the bulk of development costs, making failures common and costly.
